BioLineRx (BLRX) Liabilities and Shareholders Equity (2012 - 2025)

BioLineRx's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $40.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 5.14% year-over-year to $40.9 million; the TTM figure through Dec 2025 stood at $167.5 million (down 19.42% YoY), while the FY2025 annual figure was $40.9 million, up 5.14% from the prior year.
• Liabilities and Shareholders Equity was $40.9 million for Q4 2025 at BioLineRx, up from $39.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $91.3 million in Q2 2021 to a low of $38.9 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $63.2 million across 5 years, with a median of $64.3 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity soared 88.76% in 2021, then plunged 39.14% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $81.4 million in 2021, then dropped by 6.15% to $76.4 million in 2022, then dropped by 16.31% to $63.9 million in 2023, then tumbled by 39.14% to $38.9 million in 2024, then increased by 5.14% to $40.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $40.9 million (Q4 2025), $39.8 million (Q3 2025), and $43.3 million (Q2 2025), per Business Quant data.